![Alzheimer image](https://groundnews.b-cdn.net/interests/1e9ed030fbd621c74a310f14c6cad59186e90c09.jpg)
News from Alzheimer
Media Bias Breakdown
How is the media covering Alzheimer?Alzheimer often is covered by Center Media sources.
25%
Center: 55%
20%
Stay current with all the latest and breaking news about Alzheimer, compare headlines and perspectives between news sources on stories happening today. In total, 808 stories have been published about Alzheimer which Ground News has aggregated in the past 3 months.
Location of Coverage About AlzheimerBased on 808 recent stories
15% Local Coverage62% National Coverage23% International Coverage
Media Bias Breakdown
How is the media covering Alzheimer?Alzheimer often is covered by Center Media sources.
25%
Center: 55%
20%
Top Alzheimer News
Latest News Stories
Alzheimer · SloveniaThe European Medicines Agency (EMA) has recommended that a marketing authorization for the drug Leqembi, which is intended to slow down Alzheimer's disease in the early stages and is authorized in the US, not be issued in the European Union. It has assessed that the perceived effect of slowing the decline of cognitive abilities does not outweigh the risk of serious adverse effects.See the Story
Ema approved drugs for slowing Alzheimer's disease.
100% Center coverage: 1 sources
Alzheimer · ItalyRoma, 26 luglio 2024 – "Il rischio di gravi effetti collaterali è superiore all'effetto positivo atteso”. Con questa motivazione l'Agenzia europea per i medicinali ha respinto la raccomandazione per il farmaco Lecanemab contro l'Alzheimer. In particolare "il Comitato per i medicinali per uso umano" dell'Ema "ha raccomandato di non concedere un'autorizzazione all'immissione in commercio per Leqembi", facendo riferimento in particolare all'insorge…See the Story
Ema blocks Alzheimer's drug: 'Risk of side effects outweigh the benefits'
Alzheimer · NetherlandsThe medicine works differently than existing ahlzeimer medications and slightly slows cognitive decline in patients. But according to the EMA, the risk of side effects is too great.See the Story
European regulator issues negative advice on American-approved Alzheimer's drug
100% Left coverage: 1 sources
Alzheimer · Rio De JaneiroLeqembi would reduce beta-amyloid protein plaques, present in neurodegenerative disease. The European Medicines Agency (EMA) rejected the Alzheimer's drug, called Leqembi, a collaboration between the Japanese pharmaceutical Eisai and the American Biogen. In July of last year, the Food and Drug Administration (FDA), of the United States, gave full approval to the medicine.See the Story
European Union rejects new Alzheimer's treatment approved in the US: 'not worth the risk of serious side effects'.
Alzheimer · NetherlandsA potential cure for Alzheimer's disease is unlikely to be on the market for the time being. A committee of the European regulator, the European Medicines Agency (EMA), recommends rejecting the drug Lecanemab. The final decision is up to the European Commission, but it usually takes over the advice of the Amsterdam-based watchdog.See the Story
European watchdog sees nothing in Alzheimer's drug: 'Too high risk of side effects.'
100% Right coverage: 1 sources
Alzheimer · PakistanThe European Union’s drugs regulator has rejected Eisai and Biogen’s Leqembi treatment for early Alzheimer’s disease, saying the risk of serious brain swelling did not outweigh its small impact on slowing cognitive decline. The decision, released on Friday, is a blow to the companies as the drug faces slow take-up in the United States. Biogen’s shares fell 5% to $216.28 in early US trading. Eisai and Biogen said they will seek re-examination of …See the Story